ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction TodayACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that ACELYRIN stockholders vote “FOR” ...

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (Nasdaq: ALMS) is the best path forward and the most value-maximizing outco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-K ________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to __________________ Commission file number ...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue t ...

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis and ACELYRIN t ...

Core Viewpoint - ACELYRIN, INC. has determined that the unsolicited interest from Concentra Biosciences is not expected to yield a superior proposal compared to the planned all-stock merger with Alumis Inc, which is believed to maximize long-term value for ACELYRIN stockholders [1][2] Company Overview - ACELYRIN, INC. is a late-stage clinical biopharma company focused on developing transformative medicines in immunology, with its lead program being lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease treatment [4] Transaction Details - The all-stock transaction with Alumis is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions [2] - ACELYRIN's Board of Directors continues to recommend that stockholders support the merger with Alumis [2] Advisory Information - Guggenheim Securities, LLC is serving as the financial advisor to ACELYRIN, while Fenwick & West LLP and Paul Hastings LLP are providing legal counsel [3]

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the r ...

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Acelyrin, Inc. (Nasdaq: SLRN), relating to the proposed merger with Alumis Inc. Under the terms of the agreement, Acelyrin stockholders will receive 0.4274 shares of Alumis common stock per sh ...

Exhibit 2.1 STRICTLY CONFIDENTIAL Proposed Execution Version AGREEMENT AND PLAN OF MERGER by and among ALUMIS INC., ARROW MERGER SUB, INC. and ACELYRIN, INC. Dated as of February 6, 2025 TABLE OF CONTENTS | | | Page | | --- | --- | --- | | | ARTICLE I THE MERGER; CLOSING; SURVIVING CORPORATION | 2 | | 1.1 | The Merger | 2 | | 1.2 | Closing | 2 | | 1.3 | Effective Time | 3 | | 1.4 | Certificate of Incorporation | 3 | | 1.5 | Bylaws | 3 | | 1.6 | Directors of the Surviving Corporation | 3 | | 1.7 | Officers o ...

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical reado ...